Despite a global increase in ZFP36 expression, the lowest levels of ZFP36 activation after treatment were observed in patients with the greatest residual tumor burden, highlighting the clear effect that functional TTP appears to be having on response to therapy. This evidence concerns the gene ZFP36 and neoplasm.